Emerging drug profile: cyclin-dependent kinase inhibitors

Related Experiment Video

Updated: May 13, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

James S Blachly1, John C Byrd

  • 1Division of Hematology.

Leukemia & Lymphoma
|March 16, 2013
PubMed

Insights

Cyclin-dependent kinase (CDK) inhibitors are promising targeted cancer therapies, particularly for chronic lymphocytic leukemia (CLL). Second-generation inhibitors like dinaciclib show improved potency and selectivity over earlier agents such as flavopiridol.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies are increasingly replacing traditional chemotherapy in cancer treatment.
  • Understanding cellular machinery is crucial for developing novel cancer therapeutics.
  • Cyclin-dependent kinase (CDK) inhibitors represent a key class of targeted agents.

Purpose of the Study:

  • To review the current knowledge of CDK inhibitors, focusing on their application in chronic lymphocytic leukemia (CLL).
  • To evaluate the efficacy and limitations of first-generation CDK inhibitors like flavopiridol (alvocidib).
  • To discuss the development and potential of second-generation CDK inhibitors, such as dinaciclib, and future combination therapies.

Main Methods:

  • Review of existing scientific literature on CDK inhibitors.
  • Analysis of preclinical and clinical data for flavopiridol and dinaciclib.
  • Discussion of the mechanism of action and therapeutic potential of CDK inhibitors in CLL.

Main Results:

  • Flavopiridol (alvocidib) demonstrates significant in vitro and in vivo cytotoxicity but has limitations including a narrow therapeutic window and off-target effects.
  • Dinaciclib, a second-generation CDK inhibitor, exhibits greater potency and selectivity, with a substantially improved therapeutic index.
  • Dinaciclib is currently undergoing Phase III clinical trials.

Conclusions:

  • CDK inhibitors are a vital area of targeted cancer therapy research, especially for CLL.
  • Second-generation inhibitors like dinaciclib offer improved safety and efficacy profiles compared to earlier agents.
  • Combination therapies involving CDK inhibitors hold promise for future cancer treatment strategies.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.